Altimmune (ALT) Accumulated Depreciation (2016 - 2025)
Altimmune (ALT) posted quarterly Accumulated Depreciation of $2.3 million for Q4 2025, up 5.06% year-over-year from $2.2 million in Q4 2024, and up 5.06% quarter-over-quarter from $2.2 million in Q4 2024.
Altimmune (ALT) Accumulated Depreciation (2016 - 2025) Analysis & Trends
Altimmune (ALT) has reported Accumulated Depreciation for 10 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Depreciation rose 5.06% year-over-year to $2.3 million; the TTM figure through Dec 2025 stood at $2.3 million (up 5.06% YoY), while the FY2025 annual figure was $2.3 million, up 5.06% from the prior year.
- Accumulated Depreciation climbed to $2.3 million in Q4 2025 per ALT's latest filing, from $2.2 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $2.3 million in Q4 2025 and bottomed at $1.1 million in Q1 2022.
- Historically, Accumulated Depreciation has averaged $1.9 million across 5 years, with a median of $1.9 million in 2021.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation slumped 36.08% — and 2023, when it soared 31.84%.
- Altimmune's Accumulated Depreciation stood at $2.0 million in 2021, then slipped by 26.82% to $1.5 million in 2022, then soared by 31.84% to $2.0 million in 2023, then advanced by 12.05% to $2.2 million in 2024, then increased by 5.06% to $2.3 million in 2025.
- Business Quant data shows ALT's Accumulated Depreciation at $2.3 million in Q4 2025, $2.2 million in Q4 2024, and $2.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Dec 31, 2022 | 1.50 Mn |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 2.05 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Jun 30, 2021 | 1.83 Mn |
| Mar 31, 2021 | 1.76 Mn |
| Dec 31, 2020 | 1.60 Mn |
| Dec 31, 2019 | 1.35 Mn |
| Dec 31, 2018 | 1.11 Mn |
| Dec 31, 2017 | 951,798.00 |
| Dec 31, 2016 | 905,310.00 |